Skip to main content

Table 3 STROBE statement—checklist of items that should be included in reports of cross-sectional studies [32]

From: Influence of sexual maturation status on the relationship between body adiposity indicators and age: a cross-sectional study

 

Item no.

Recommendation

Pages

Title and abstract

1

(a) Indicate the study’s design with a commonly used term in the title or the abstract

2

 

(b) Provide in the abstract an informative and balanced summary of what was done and what was found

2

Introduction

Background/rationale

2

Explain the scientific background and rationale for the investigation being reported

3

Objectives

3

State specific objectives, including any pre-specified hypotheses

3

Methods

Study design

4

Present key elements of study design early in the paper

4

Setting

5

Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection

4

Participants

6

(a) Give the eligibility criteria and the sources and methods of selection of participants

4

Variables

7

Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable

4–5

Data sources/measurement

8*

For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group

5

Bias

9

Describe any efforts to address potential sources of bias

Study size

10

Explain how the study size was arrived at

4–5

Quantitative variables

11

Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why

4–5

Statistical methods

12

(a) Describe all statistical methods, including those used to control for confounding

5

 

(b) Describe any methods used to examine subgroups and interactions

5

 

(c) Explain how missing data were addressed

5

 

(d) If applicable, describe analytical methods taking account of sampling strategy

5

 

(e) Describe any sensitivity analyses

5

Results

Participants

13*

(a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed

7

 

(b) Give reasons for non-participation at each stage

4–5

 

(c) Consider use of a flow diagram

Descriptive data

14*

(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders

6

 

(b) Indicate number of participants with missing data for each variable of interest

Outcome data

15*

Report numbers of outcome events or summary measures

6

Main results

16

(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included

6

 

(b) Report category boundaries when continuous variables were categorized

6

 

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

6

Other analyses

17

Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses

6

Discussion

Key results

18

Summarize key results with reference to study objectives

7

Limitations

19

Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias

Interpretation

20

Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence

7–8

Generalizability

21

Discuss the generalizability (external validity) of the study results

7–8

Other information

Funding

22

Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

09

  1. An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org
  2. * Give information separately for exposed and unexposed groups